COMMUNIQUÉS West-GlobeNewswire

First Choice Healthcare Solutions Appoints Phillip Keller as Interim CEO
19/11/2018
The Independent Board of Directors Announce Additional Updates MELBOURNE, Fla., Nov. 19, 2018 (GLOBE NEWSWIRE) -- First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) ("First Choice" or the "Company"), a fully [...]
Fortress Biotech Announces Agreement to Sell Its Majority Stake in National Holdings Corporation to NHC Holdings, LLC, a wholly-owned subsidiary of B. Riley Financial
19/11/2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Management Changes at Rafina Innovations Inc.
19/11/2018
Glasgow, Scotland, Nov. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Rafina Innovations Inc. (formerly HCi Viocare) (OTCQB:VICA) , provides update on recent management changes. Rafina Innovations Inc. was created to [...]
Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
19/11/2018
RADNOR, Pa., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat [...]
Radient Technologies Inc. Files Provisional Patent Applications for Innovating Cannabis Supply Chain and Expands Operational Capabilities in Europe
19/11/2018
EDMONTON, Alberta, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is pleased to announce that it has now filed an additional 13 provisional patent [...]
CHMP Issues Positive Opinion on Split Dosing Regimen for DARZALEX® (daratumumab)
19/11/2018
Media Release CHMP issued positive opinion on split dosing regimen for DARZALEX Final decision from European Commission expected in the coming months Opinion supported by data from EQUULEUS (MMY1001) clinical trial [...]
Myriad Announces $50 Million Accelerated Share Repurchase Program
19/11/2018
SALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (“ASR [...]
Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
19/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate [...]
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
19/11/2018
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple solid tumour indications ( [...]
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease
19/11/2018
Planning Phase II Trial VANCOUVER, B.C., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (FRANKFURT: BTI) (OTCQB: BTHCD) (the [...]
Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference
19/11/2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
Canopy Rivers Portfolio Company Radicle Receives Licence From Health Canada to Commence Sales of Premium Craft Cultivated Product
19/11/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES TORONTO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“ Canopy Rivers ” or the “ Company ”) (TSXV:RIV) congratulates its portfolio company, [...]
Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture
19/11/2018
Joint venture to d istribute endocannabinoid-supporting products to Canadian natural health product stores and pharmacies VICTORIA, British Columbia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc [...]
Microbix Wins Business Award of Excellence
19/11/2018
Recognized with 2018 Business Innovation Award by MBOT TORONTO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it [...]
Evogene Announces Establishment of Ag-Chemicals Subsidiary – AgPlenus Ltd.
19/11/2018
Evogene’s activities relating to design and development of effective and safe next generation agro-chemical products transferred to new subsidiary REHOVOT, Israel, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ [...]
Eloxx Pharmaceuticals To Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018
19/11/2018
WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic [...]
ContraFect to Present at Piper Jaffray Health Care Conference
19/11/2018
YONKERS, N.Y., Nov. 19, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]
Avivagen’s Asian partner UNAHCO continues to ramp-up use of OxC-beta™ Livestock with new large order
19/11/2018
OTTAWA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen”), is pleased to announce that its partner in the Philippines, UNAHCO, has purchased 2 metric tonnes of OxC-beta™ Livestock. This follows a 2 [...]
BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
19/11/2018
Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. Patient dosing is ongoing in a combination [...]

Pages